Ferring's Investigational Therapy RBX2660 Demonstrates Another Potential Offering for C Diff Treatment
A clinician provides an overview of the data on the microbiota-based live biotherapeutic, RBX2660, which in phase 3 studies has shown safety and reduction in recurrent C difficile infection (rCDI).
The release of the Infectious Diseases Society of America’s 2017 guideline update for C diff treatment recommended the use of either vancomycin or fidaxomicin for first-line use therapy.
Although it is yet to be determined if this update will successfully reduce the rate of C diff recurrence, these therapies will not always successfully treat the bacterium. And as such, clinicians are looking for other therapeutics to alleviate the pain and suffering of their patients.
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, announced this week it was presenting 5 studies on it investigational biotherapeutic, RBX2660. Some of the highlights from the studies included:
- RBX2660 significantly increased gut bacteria associated with health and decreased gut bacteria associated with CDI pathology;
- And analysis of phase 3 data showed bile acid compositions shifted significantly from primary to secondary bile acid predominance after treatment.
Teena Chopra, MD, MPH, professor of Medicine, Division of Infectious Disease, Wayne State University School of Medicine, has reviewed the data and sees RBX2660's promise as an emerging therapy for rCDI.
Contagion spoke to Chopra who offered insights on the various studies and her clinical perspective on looking at this potential therapy in the treatment of C diff and recurrent C diff.
